about
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trialThe long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in SwedenLong-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in GermanyResource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data.The burden of Duchenne muscular dystrophy: an international, cross-sectional study.Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure.Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden.Costs and quality of life of patients with multiple sclerosis in EuropeCompliance to Care Guidelines for Duchenne Muscular Dystrophy.Quantifying the burden of caregiving in Duchenne muscular dystrophyCost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study.A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study.From 4S to IDEAL: the health economics of the statin trials.Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.Cost-effectiveness of statins revisited: lessons learned about the value of innovation.Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Professionals' perspectives on a market-inspired policy reform: A guiding light to the blind spots of measurement.Managerial strategies to make incentives meaningful and motivating.A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.The cost and burden of cancer in the European Union 1995-2014.Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy.Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT).Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry.The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden.The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.Patient Preferences for Treatments of Neuromuscular Diseases: A Systematic Literature Review.The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.Costs and quality of life of multiple sclerosis in Spain.Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia.Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS).Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study.Modelling the costs and effects of leflunomide in rheumatoid arthritis.The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden.Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
P50
Q28193114-0A923771-1406-4929-87BC-DBDB980F3043Q28210186-82C3B612-6966-4D56-A11C-A977EA6F4E43Q28213339-43251E73-07AB-4DC7-89E4-53ADF2BEF09AQ31150196-3C5401CC-7A71-44A3-A33D-2D84286F75BAQ33424116-B78B8875-BB1B-46B4-8AEB-B73CDE7E8AFAQ33516150-D57E427F-07E7-4F5F-A076-626B8F2A6E1DQ34079312-4057CCEF-463F-44A8-A145-C257713DFB64Q34183423-2BBCA06D-21CC-4702-B359-15D28D496543Q34496448-DF04CB7B-6C67-45C1-8ADA-4C9BA8AE93A7Q35845343-73F27A0E-AF72-42CA-B0EF-8C4074DE6D6EQ36142777-225070BE-E22E-493D-A073-1B7C34D35CF4Q36560420-F968FD27-65F5-4026-B03F-081106E8BBA8Q36879404-1C86C1DA-FACA-4EED-A636-DAA483EF20B2Q36907864-27067878-EF81-46F5-80F9-FED28E62A239Q37105702-8734A95C-98B0-47C1-8501-57C58B55DB93Q37302117-88ACB1A0-1545-4078-8326-07626E410631Q37451199-BB4F266F-7596-481A-8D86-44672C85D62FQ37597697-37C170EF-26CE-46C9-8FA5-AC01B1BD4564Q37870094-1EB7EF2C-3E93-4868-9CDC-1ED980B5C517Q38468459-B36CD275-0F7E-4825-B6C9-0AAFAD0111A4Q38612448-1BA7FA44-CF7F-45E2-837D-A4063B2EAECDQ38783982-BB586EC8-4A32-476F-BB6B-0E32AFC26E0DQ38797658-C369E61C-155F-426E-9CAD-E7AD97154C91Q38992196-B4BA8B40-41D2-4261-8632-283BABA52E26Q39428179-6013C2D1-81B5-4A66-8F2D-837BD9E9DFC4Q40260838-2DB9E36B-AF42-4500-9E7C-99C7BD342133Q40413384-9CCBF931-1F8F-4E32-B468-FCB5D5BB2722Q40819694-FC9CEA23-A1DB-4599-B5C5-9AA080479EEBQ42623432-2263C848-71DA-47A6-A81B-F99141AA2C89Q42661766-620901EA-A917-4A51-BBB1-9711BA46E33CQ43075522-399EF520-E0E7-4A69-8555-9697E57FCDBFQ43442158-D725EBAD-EB3F-47D2-938F-356C6A3DB8CBQ43684192-B9FF4D0F-7459-4DB1-8457-11416DC3488BQ43912878-03C762A5-1DEC-401E-AB56-653541F14367Q44569632-C0B54E74-BD98-41B9-B84E-28F9452AD564Q44839970-337FD830-ADC5-4DBC-893A-0B9BBC175225Q45173971-3308DB66-CFB3-41F2-A55B-78F734782A65Q45194282-1AC90C8B-F0FD-415A-A53D-2325591094DDQ45194287-C1263B6C-BD90-447B-B653-904D189A8CEAQ45259486-33978BBD-2B51-4D8B-A19E-4350F79EC7BC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Lindgren
@ast
Peter Lindgren
@en
Peter Lindgren
@es
Peter Lindgren
@nl
Peter Lindgren
@sl
type
label
Peter Lindgren
@ast
Peter Lindgren
@en
Peter Lindgren
@es
Peter Lindgren
@nl
Peter Lindgren
@sl
prefLabel
Peter Lindgren
@ast
Peter Lindgren
@en
Peter Lindgren
@es
Peter Lindgren
@nl
Peter Lindgren
@sl
P106
P21
P31
P496
0000-0002-8238-8189